1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Collin Blakely: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Capmatinib, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer | Phase 1 | Terminated | Collin Blakely | 3 | 2022-08-10 | 2024-06-11 |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Osimertinib, Alisertib - Lung Cancer Metastatic, EGFR Gene Mutation | Phase 1 | Completed | Collin Blakely | 23 | 2019-11-12 | 2026-08-11 |
Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
MLN 8237 (1) · capmatinib (1) · osimertinib (1) · trametinib (1)
United States (2)